Cookie-Richtlinie

Wir verwenden Cookies, um Informationen über die Leistung und Nutzung der Website zu erfassen und zu analysieren sowie um sicherzustellen, dass Ihre Navigation der Website erfolgreich verläuft. Wenn Sie rechts auf die Schaltfläche „Okay“ oder auf einen Inhalt auf der Website klicken, stimmen Sie damit dem Setzen von Cookies auf Ihrem Computer zu. Weitere Informationen finden Sie in unserer Datenschutzerklärung. 

 
Regionen
 
WEBSEITEN
  • United States (English)
  • International (English)
  • Chinesisch (中文)
  • Französisch (Français)
  • Deutsch
  • Italienisch (Italiano)
  • Japanisch (日本語)
  • Russisch (Русский)
 

YesNo
  • Investor Relations
  • ANMELDEN
    • Haemonetics
    • HSS Client Login
    • Software Download Center
  • REGISTRIEREN
  • Home
  • Produkte
     
    Internationale ProdukteUS-Produkte
    Geräte
    Geräte für BlutZentren
    • ACP 215
    • PCS 2
    Geräte für Plasmazentren
    • MCS+
    OP- und Diagnosegeräte
    • Cell Saver 5+
    • Cell Saver Elite
    • TEG
    Software
    Software für Plasmazentren
    • eLynx

     
  • Lösungen
     
    Blutmanagementlösungen
    • Lösungen für Blutspendezentren
    • Lösungen für Krankenhäuser
    • Lösungen für Plasmazentren
     
  • Infocenter
     
    Forschung und Publikationen
    • White Papers & Klinische Bewertungen (in Englisch)
    • Referenzlisten (in Englisch)
    • Poster-Abstracts (in Englisch)
     
  • Über Haemonetics
     
    Das Unternehmen
    • Überblick
    • Unternehmensgeschichte
    • Führungsteam
    • Standorte
    Investor Relations
    • Investor Relations: Startseite
    • Informationen zur Aktie
    • Erträge
    • Prognosen & Leitlinien
    Corporate Responsibility
    • Corporate Responsibility at Haemonetics
    Donors Make It Matter
    • Donors Make It Matter Campaign
    Neuigkeiten und Termine
    • Neuigkeiten
    • Terminkalender
    Stellenangebote
    • Stellenangebote – Überblick

    Grants

       
    • Kundenservice

    YesNo
    • Home
    • Infocenter
    • Forschung und Publikationen
    • Poster-Abstracts (in Englisch)
    • Kontakt
    • Drucken
    • Teilen

    Poster-Abstracts (in Englisch)

    • AABB 2016

      Orlando, Florida

      • A novel approach for fat removal while maintaining blood quality in a discontinuous autotransfusion device - concept and evaluation
        Conclusions: Based on observations using a transparent centrifugation system, a hypothesis is presented to explain the accumulation of fat in the centrifuge bowl, both in spinning and stopped configurations. Modifications in process parameters and sequence resulted in the development of a dedicated fat removal program. This novel program significantly improves fat removal by the Latham bowl based autotransfusion device CS Elite, thus yielding results equivalent to the continuous autotransfusion system (CATS).
    • AABB 2012

      Boston, Massachusetts

      • Age of Blood Transfused In the United States: Data for 166,208 Transfusions
        Conclusions: For the hospitals studied, the current RBC supply chain and inventory management systems result in 47% of RBC units being transfused more than 3 weeks and 25% more than 4 weeks after their donation. Modifying the current supply chain to provide “fresher” blood will require substantial practice change and system redesign.
      • Blood Transfusion and Length of Stay: How Are They Related?
        Results: LOS was related to Nadir Hgb irrespective of transfusion status. Within each group of Nadir Hgb (except <7 g/dL), patients who received allogeneic blood had longer LOS than those who did not. Patients who received PAD (n=1179) had both longer LOS (3.50 vs. 3.07 days) and higher allogeneic transfusion rates (27.1% vs.17.3%) than those who did not receive PAD.
      • Variability in Transfusion Practice – Beyond Cardiac Surgery
        Methods: We queried a proprietary blood management business intelligence portal (IMPACT® Online, Haemonetics, Braintree, MA) and identified 9 noncardiac procedures associated with substantial red cell (RBC) transfusions. For each procedure, we determined the mean RBC transfusion and utilization rate for the entire hospital stay as well as the standard deviation (SD) of those rates among the participating hospitals (those that contributed at least 20 patients to each data set).
    • SABM 2012

      Pittsburgh, Pennsylvania

      • Periodic data review assures sustainability of blood management programs
        Results: Dramatic reductions in the use of PAD were achieved in each hospital. These improvements were not only sustained but continued during follow up. Similar success and sustainability was seen in the cardiac surgical interventions as reflected in decreased RBC utilization (units/patient including untransfused patients) for patients having coronary artery surgery (CABG).
      • Two unit dosing leads to excess transfusion
        Methods: Using a blood management business intelligence portal (IMPACT® Online, Haemonetics®, Braintree, MA) we determined the hematocrit at discharge of transfused patients who had either unilateral total hip or knee replacements during 2010 or 2011. From a group of 20,758 patients at 15 US hospitals, we removed 105 with incomplete data, 545 without a hematocrit following their last transfusion and 1,194 who received preoperatively donated autologous blood. Of the remaining 18,914, 3,033(16%) received allogeneic RBC.
    • Poster Archives

      Click here to view posters from previous years.
    • Kontakt
    • Nutzungsbedingungen
    • Qualität
    • Datenschutzerklärung
    • Inhaltsübersicht

    © 2011-2020 Haemonetics Corporation